Literature DB >> 11967993

Relaxin activates the MAP kinase pathway in human endometrial stromal cells.

Qiang Zhang1, Shu-Hui Liu, Mark Erikson, Martyn Lewis, Elaine Unemori.   

Abstract

The reproductive hormone, relaxin, is structurally similar to insulin and insulin-like growth factor (IGF). Although a number of cellular responses to relaxin have been described, intracellular signaling mechanisms that link relaxin receptor engagement to alterations in gene expression remain uncharacterized. In the present study, relaxin treatment of a well-characterized target, human endometrial stromal cells, resulted in rapid activation of p42/44 mitogen-activated protein (MAP) kinase, as well as of MAPK (or ERK) kinase (MEK). Using a selective chemical inhibitor of MEK, it was further demonstrated that MEK phosphorylation is critical for relaxin-induced MAP kinase activation. Relaxin treatment also induced MAP kinase activation in THP-1 monocytic cells and in human smooth muscle cells, indicating that it may be a major signaling transducer utilized by the relaxin receptor. In contrast to insulin or IGF-1, relaxin did not trigger the PI 3-kinase/Akt pathway, perhaps accounting in part for relaxin's unique biological profile. Relaxin was also found to cause activation of the transcription factor CREB, a substrate of the MAP kinase pathway. Finally, activation of the MAP kinase pathway was shown to be essential for optimal stimulation of expression of the gene for vascular endothelial growth factor. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967993     DOI: 10.1002/jcb.10150

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  16 in total

1.  Relaxin stimulates cAMP production in MCF-7 cells upon overexpression of type V adenylyl cyclase.

Authors:  Bao T Nguyen; Carmen W Dessauer
Journal:  Ann N Y Acad Sci       Date:  2005-05       Impact factor: 5.691

Review 2.  Relaxin family peptide receptors--former orphans reunite with their parent ligands to activate multiple signalling pathways.

Authors:  M L Halls; E T van der Westhuizen; R A D Bathgate; R J Summers
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

Review 3.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

Review 4.  Relaxin: antifibrotic properties and effects in models of disease.

Authors:  Chrishan S Samuel
Journal:  Clin Med Res       Date:  2005-11

Review 5.  Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Authors:  Michelle L Halls
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

6.  Relaxin stimulates multiple signaling pathways: activation of cAMP, PI3K, and PKCzeta in THP-1 cells.

Authors:  Carmen W Dessauer; Bao T Nguyen
Journal:  Ann N Y Acad Sci       Date:  2005-05       Impact factor: 5.691

Review 7.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

Review 8.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

9.  Relaxin signaling activates peroxisome proliferator-activated receptor gamma.

Authors:  Sudhir Singh; Robert G Bennett
Journal:  Mol Cell Endocrinol       Date:  2009-08-25       Impact factor: 4.102

Review 10.  Relaxin, a pleiotropic vasodilator for the treatment of heart failure.

Authors:  Sam L Teichman; Elaine Unemori; Thomas Dschietzig; Kirk Conrad; Adriaan A Voors; John R Teerlink; G Michael Felker; Marco Metra; Gad Cotter
Journal:  Heart Fail Rev       Date:  2008-12-20       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.